SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 64,913.05 |
| Enterprise Value ($M) | 48,984.85 |
| Book Value ($M) | 29,353.60 |
| Book Value / Share | 279.01 |
| Price / Book | 2.21 |
| NCAV ($M) | 18,806.00 |
| NCAV / Share | 178.75 |
| Price / NCAV | 3.45 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.14 |
| Return on Assets (ROA) | 0.13 |
| Return on Equity (ROE) | 0.16 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.94 |
| Current Ratio | 5.57 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 27,211.80 |
| Assets | 37,759.40 |
| Liabilities | 8,405.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 14,202.00 |
| Operating Income | 4,227.20 |
| Net Income | 4,412.60 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 4,420.50 |
| Cash from Investing | -2,468.10 |
| Cash from Financing | -2,200.50 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 7.60 | -20.63 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 151,626 | 776,169 | 19.54 | |
| 199,510 | 911,548 | 21.89 | |
| 205,026 | 813,068 | 25.22 | |
| 105,220 | 396,622 | 26.53 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| QURE – uniQure N.V. | RARE – Ultragenyx Pharmaceutical Inc. |
| RDUS – Radius Recycling, Inc. | REPL – Replimune Group, Inc. |
| RGEN – Repligen Corporation |
Financial data and stock pages provided by
Fintel.io